Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2025)

Historic Interest Expenses for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $98000.0.

  • Kymera Therapeutics' Interest Expenses rose 6333.33% to $98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $337000.0, marking a year-over-year increase of 3925.62%. This contributed to the annual value of $249000.0 for FY2024, which is 2704.08% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Interest Expenses is $98000.0, which was up 6333.33% from $108000.0 recorded in Q2 2025.
  • Kymera Therapeutics' Interest Expenses' 5-year high stood at $108000.0 during Q2 2025, with a 5-year trough of $24000.0 in Q1 2021.
  • Its 5-year average for Interest Expenses is $56473.7, with a median of $55000.0 in 2023.
  • In the last 5 years, Kymera Therapeutics' Interest Expenses soared by 15000.0% in 2021 and then tumbled by 4857.14% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Interest Expenses (Quarter) stood at $51000.0 in 2021, then grew by 15.69% to $59000.0 in 2022, then decreased by 11.86% to $52000.0 in 2023, then grew by 13.46% to $59000.0 in 2024, then surged by 66.1% to $98000.0 in 2025.
  • Its Interest Expenses stands at $98000.0 for Q3 2025, versus $108000.0 for Q2 2025 and $72000.0 for Q1 2025.